Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021-Reference-Cited by-全球学者库

Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021

Published:2021-12-16 Issue:50 Volume:26 Page:
ISSN:1560-7917
Container-title:Eurosurveillance
language:en
Short-container-title:

Author:

Brandal Lin T.¹,MacDonald Emily¹,Veneti Lamprini¹,Ravlo Tine²,Lange Heidi¹,Naseer Umaer¹,Feruglio Siri¹,Bragstad Karoline¹,Hungnes Olav¹,Ødeskaug Liz E.¹,Hagen Frode²,Hanch-Hansen Kristian E.²,Lind Andreas³,Watle Sara Viksmoen¹,Taxt Arne M.¹,Johansen Mia¹,Vold Line¹,Aavitsland Preben¹,Nygård Karin¹,Madslien Elisabeth H.¹

Affiliation:

1. Norwegian Institute of Public Health, Oslo, Norway

2. Municipality of Oslo, Norway

3. Department of Microbiology, Oslo University Hospital, Oslo, Norway

Abstract

In late November 2021, an outbreak of Omicron SARS-CoV-2 following a Christmas party with 117 attendees was detected in Oslo, Norway. We observed an attack rate of 74% and most cases developed symptoms. As at 13 December, none have been hospitalised. Most participants were 30–50 years old. Ninety-six percent of them were fully vaccinated. These findings corroborate reports that the Omicron variant may be more transmissible, and that vaccination may be less effective in preventing infection compared with Delta.

Publisher

European Centre for Disease Control and Prevention (ECDC)

Subject

Virology,Public Health, Environmental and Occupational Health,Epidemiology

Reference16 articles.

1. World Health Organization (WHO). Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. Geneva: WHO. [Accessed: 6 Dec 2021]. Available from: https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern

2. European Centre for Disease Prevention and Control (ECDC). Threat Assessment Brief: Implications of the further emergence and spread of the SARS CoV 2 B.1.1.529 variant of concern (Omicron) for the EU/EEA first update. Stockholm: ECDC. [Accessed: 6 Dec 2021]. Available from: https://www.ecdc.europa.eu/en/publications-data/covid-19-threat-assessment-spread-omicron-first-update

3. Norwegian Institute of Public Health (NIPH). Spesifikke TISK-tiltak for omikronvarianten. [Specific testing, isolation, contact tracing and quarantine (TISK) measures for the Omicron variant]. Oslo: FHI. [Accessed: 8 Dec 2021]. Norwegian. Available from: https://www.fhi.no/nettpub/coronavirus/testing/tisk/?term=&h=1#spesifikke-tisktiltak-for-omikronvarianten

4. United Kingdom Health Security Agency. Risk assessment for SARS-CoV_2 variant: Omicron VOC-21NOV-01 (B.1.1.529). London: UK Health Security Agency. [Accessed: 8 Dec 2021]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1038442/3_December-2021-risk-assessment-for-SARS_Omicron_VOC-21NOV-01_B.1.1.529.pdf

5. Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings - Barnstable County, Massachusetts, July 2021.;Brown;MMWR Morb Mortal Wkly Rep,2021

Cited by 250 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An age-cohort simulation model for generating COVID-19 scenarios: A study from Ireland's pandemic response;European Journal of Operational Research;2024-02

2. SARS-CoV-2 induces inflammation and intracranial infection through the olfactory epithelium-olfactory bulb pathway in non-human primates;Journal of Neuroimmunology;2024-02

3. A comprehensive review on immunogen and immune-response proteins of SARS-CoV-2 and their applications in prevention, diagnosis, and treatment of COVID-19;International Journal of Biological Macromolecules;2024-02

4. Source of SARS-CoV-2 infection: results from a series of 584,846 cases in France from October 2020 to August 2022;BMC Public Health;2024-01-30

5. Quantifying Exhaled Particles in Healthy Humans During Various Respiratory Activities Under Realistic Conditions;Journal of Aerosol Medicine and Pulmonary Drug Delivery;2024-01-29